Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mersana Therapeutics, Inc.MRSN · Entity 69982 | Chief Medical Officer | February 02, 2018 | February 06, 2018 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | President, R&D | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mersana Therapeutics, Inc.
Report date February 02, 2018 · Filed February 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.23 · Expires 2028-02-01 | Direct | 56,884 |
Reported balance
After 2018-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-02 · Grant · Acquired 56,884 · Balance 56,884 F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018.
Relay Therapeutics, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 399,130 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Sale · Disposed 8,530 · Balance 399,130 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 10,025 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 10,025 shares underlying restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fusion Pharmaceuticals Inc.
Report date June 04, 2024 · Filed June 04, 2024
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Disposition to issuer · Disposed 34,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 9, 2026 20:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,530 | $18.97 | $161,814.10 |
DisclosureSEC source: 0001193125-26-386473 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,130 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 10,025 shares underlying restricted stock units. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:12 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,237 | $18.61 | $41,630.57 |
DisclosureSEC source: 0001193125-26-326137 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,660 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,012 shares of restricted stock units ("RSUs") on July 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 10,025 shares underlying RSUs. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:11 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,660 | $18.71 | $162,028.60 |
DisclosureSEC source: 0001193125-26-298688 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,897 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.45 to $19.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 15,037 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 93,456 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001193125-26-281059 · ownership.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,456 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder vested in equal quarterly installments over the remaining thirty-six (36) months. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 93,456 | $16.94 | $1,583,144.64 |
DisclosureSEC source: 0001193125-26-281059 · ownership.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,557 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 15,037 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 93,456 | $4.12 | $385,038.72 |
DisclosureSEC source: 0001193125-26-281059 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 512,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · balance_after: Includes 15,037 shares underlying restricted stock units. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 20:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,490 | $14.79 | $22,037.10 |
DisclosureSEC source: 0001193125-26-197395 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,557 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,012 shares of restricted stock units ("RSUs") on April 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 15,037 shares underlying RSUs. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 21:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,686 | $8.45 | $22,696.70 |
DisclosureSEC source: 0001193125-26-029415 · ownership.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,047 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,072 shares of RSUs on January 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 20,049 shares underlying RSUs. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 18,895 | $7.62 | $143,979.90 |
DisclosureSEC source: 0001193125-26-029415 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,733 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 59,550 shares of restricted stock units ("RSUs") on January 26, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 29,121 shares underlying RSUs. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 575,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001193125-26-014111 · ownership.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2036-01-12 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:12 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 30,897 | $7.29 | $225,239.13 |
DisclosureSEC source: 0001193125-25-258557 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,823 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 68,622 shares of restricted stock units ("RSUs") on October 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 168,866 shares underlying RSUs. Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 20:54 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 26,701 | $3.68 | $98,259.68 |
DisclosureSEC source: 0000950170-25-100365 · ownership.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 552,720 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 59,550 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 237,488 shares underlying RSUs. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:54 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 4,069 | $3.74 | $15,218.06 |
DisclosureSEC source: 0000950170-25-100365 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,421 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,072 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 297,038 shares underlying RSUs. Read SEC document |
| April 30, 2025 Filed May 1, 2025 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 27,472 | $3.00 | $82,416.00 |
DisclosureSEC source: 0000950170-25-061365 · ownership.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583,490 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 59,550 shares of RSUs on April 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 306,110 shares underlying RSUs. Read SEC document |
| April 28, 2025 Filed May 1, 2025 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 4,090 | $3.17 | $12,965.30 |
DisclosureSEC source: 0000950170-25-061365 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610,962 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,071 shares of restricted stock units ("RSUs") on April 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 365,660 shares underlying RSUs. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 20:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 986 | $2.84 | $2,800.24 |
DisclosureSEC source: 0000950170-25-047762 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,052 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,188 shares of restricted stock units ("RSUs") on March 26, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 374,731 shares underlying RSUs. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 02:06 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 30,823 | $4.42 | $136,237.66 |
DisclosureSEC source: 0000950170-25-011319 · ownership.xml · nonDerivative · entry 4 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 616,038 F7 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 88,200 shares of RSUs on January 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F8 · balance_after: Includes 376,919 shares underlying RSUs. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 02:06 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 46,407 | $4.55 | $211,151.85 |
DisclosureSEC source: 0000950170-25-011319 · ownership.xml · nonDerivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 646,861 F5 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 150,000 shares of RSUs on January 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F6 · balance_after: Includes 465,119 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:06 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 176,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011319 · ownership.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 693,268 F3 · shares: Represents RSUs granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F4 · balance_after: Includes 615,119 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:06 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 3,220 | $4.63 | $14,908.60 |
DisclosureSEC source: 0000950170-25-011319 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,868 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,071 shares of restricted stock units ("RSUs") on January 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 438,719 shares underlying RSUs. Read SEC document |
| January 10, 2025 Filed Jan 15, 2025 02:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000950170-25-005565 · ownership.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2035-01-09 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 657 | $4.38 | $2,877.66 |
DisclosureSEC source: 0000950170-24-141598 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,088 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on December 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 447,790 shares underlying RSUs. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:08 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,688 | $6.06 | $16,289.28 |
DisclosureSEC source: 0000950170-24-118981 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,745 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,072 shares of restricted stock units ("RSUs") on October 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 449,977 shares underlying RSUs. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 648 | $7.51 | $4,866.48 |
DisclosureSEC source: 0000950170-24-110808 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,433 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,188 shares of restricted stock units ("RSUs") on September 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 459,049 shares underlying RSUs. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 22:42 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,698 | $8.85 | $23,877.30 |
DisclosureSEC source: 0000950170-24-088812 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,081 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,072 shares of restricted stock units ("RSUs") on July 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 461,237 shares underlying RSUs. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:42 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 648 | $6.26 | $4,056.48 |
DisclosureSEC source: 0000950170-24-079692 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,779 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on June 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 470,309 shares underlying RSUs. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:17 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0000950170-24-068867 · ownership.xml · derivative · entry 4 Bergstrom Donald A · CIK 0001709772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:17 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0000950170-24-068867 · ownership.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:17 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $8.15 | Not disclosed |
DisclosureSEC source: 0000950170-24-068867 · ownership.xml · derivative · entry 2 Bergstrom Donald A · CIK 0001709772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:17 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,000 | Not disclosed Strike: $10.59 | Not disclosed |
DisclosureSEC source: 0000950170-24-068867 · ownership.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires not disclosed F1 · security: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 00:30 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,686 | $6.38 | $17,136.68 |
DisclosureSEC source: 0000950170-24-050146 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,427 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,071 shares of restricted stock units ("RSUs") on April 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 472,496 shares underlying RSUs. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 765 | $7.70 | $5,890.50 |
DisclosureSEC source: 0000950170-24-038656 · ownership.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,113 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,188 shares of restricted stock units ("RSUs") on March 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 481,567 shares underlying RSUs. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:08 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 3,178 | $9.64 | $30,635.92 |
DisclosureSEC source: 0001209191-24-002470 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,878 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,072 shares of restricted stock units ("RSUs") on January 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 483,755 shares underlying RSUs. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001837 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,056 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 492,827 shares underlying RSUs Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 977 | $11.51 | $11,245.27 |
DisclosureSEC source: 0001209191-23-059996 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,056 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on December 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 192,827 shares underlying RSUs. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:14 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 3,451 | $6.03 | $20,809.53 |
DisclosureSEC source: 0001209191-23-054020 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,033 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,071 shares of restricted stock units ("RSUs") on October 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 195,014 shares underlying RSUs. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:52 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 648 | $8.38 | $5,430.24 |
DisclosureSEC source: 0001209191-23-050869 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,484 F4 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,188 shares of RSUs on September 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F5 · balance_after: Prior to the reported transaction, the amount of securities beneficially owned by the reporting person was 239,132, with 206,273 shares underlying RSUs. F6 · balance_after: Includes 204,085 shares underlying RSUs. Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 20:48 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,683 | $11.80 | $31,659.40 |
DisclosureSEC source: 0001209191-23-043838 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,904 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 9,072 shares of restricted stock units ("RSUs") on July 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 206,273 shares underlying RSUs. Read SEC document |
| June 30, 2023 Filed Sep 29, 2023 20:52 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 1,228 | $10.68 | $13,115.04 |
DisclosureSEC source: 0001209191-23-050869 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,815 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2023. F3 · balance_after: Includes 215,345 shares underlying restricted stock units ("RSUs"). Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 21:06 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 647 | $12.12 | $7,841.64 |
DisclosureSEC source: 0001209191-23-040059 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,587 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on June 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 215,345 shares underlying RSUs. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 17:04 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001209191-23-037089 · doc4.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. Read SEC document |
| April 28, 2023 Filed May 1, 2023 20:29 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,383 | $11.16 | $15,434.28 |
DisclosureSEC source: 0001209191-23-026275 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,701 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 4,059 shares of restricted stock units ("RSUs") on April 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 222,544 shares underlying RSUs. Read SEC document |
| April 28, 2023 Filed Jun 1, 2023 22:17 UTC Amendment | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,850 | $11.16 | $31,806.00 |
DisclosureSEC source: 0001209191-23-033416 · doc4a.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,234 F1 · shares: This amendment is being filed to correct the number of shares sold to cover the reporting person's income tax withholding obligations upon the vesting of 9,071 shares of restricted stock units ("RSUs") on April 27, 2023, which was inadvertently understated in the reporting person's original Form 4. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Due to the error described above, the reporting person's original Form 4 incorrectly reported that the number of shares held by the reporting person was 242,701, including 222,544 shares underlying RSUs. As reported in this amendment, the correct number of shares held by the reporting person is 241,234, including 217,532 shares underlying RSUs. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 20:49 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 763 | $15.36 | $11,719.68 |
DisclosureSEC source: 0001209191-23-021417 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,084 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on March 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 226,603 shares underlying RSUs. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,429 | $21.56 | $30,809.24 |
DisclosureSEC source: 0001209191-23-005696 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,847 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 4,059 shares of restricted stock units ("RSUs") on January 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 228,790 shares underlying RSUs. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:28 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 160,390 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004122 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,390 Underlying: Common Stock · 160,390 shares Expires 2033-01-16 F4 · derivative.exercise_date: Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:28 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 160,390 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004122 · doc4.xml · derivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,390 Underlying: Common Stock · 160,390 shares Expires 2033-01-16 F3 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:28 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 160,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004122 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,276 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 232,849 shares underlying RSUs Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 21:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 980 | $14.49 | $14,200.20 |
DisclosureSEC source: 0001209191-22-062818 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,886 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,188 shares of restricted stock units ("RSUs") on December 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 72,459 shares underlying RSUs. Read SEC document |
| November 01, 2022 Filed Nov 1, 2022 21:58 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-055116 · doc4.xml · derivative · entry 4 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,456 Underlying: Common Stock · 8,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.